CNS launches custom-fit regulatory consulting service

By Natalie Morrison

- Last updated on GMT

Related tags: Molecular biology

Clinical Network Services (CNS) has launched its new custom-fit regulatory consulting service, BioDesk.

The Australian CRO (contract research organisation) says its new offering – geared towards Phase I & II trials – is made up of an international, multi-disciplinary network of preclinical and regulatory consultants.

The company will then tailor the “ideal team” to suit each project, who will work with clients from product profiling right up to support finding investors.

Russell Neal, chief operating officer of CNS, told Outsourcing-Pharma that the level of service they can provide is unique for a company in Australia or New Zealand.

He added: Our service works because it is a sum of the parts.

For CNS’s clients, who are smaller with fewer internal resources, it is critical for them to establish trusted consultant relationships and gain applicable and strategic international regulatory advice for their programs.

“We can relate to target plans small company to small company.”

Services for all

With the appointment of gene therapy and genetically modified organisms (GMOs) expert Mark Reid, who will become the leader of the new service offering, Outsourcing-Pharma put the question to Neal whether the company would specialize in this field.

“No - we haven’t specialised, nor will we,”​ he replied.

“We provide services to all therapeutic areas and technologies. However, Mark does bring rare insight and experience to gene therapy and biological in general. “

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more